Free Trial
NASDAQ:DNLI

Denali Therapeutics Q4 2024 Earnings Report

Denali Therapeutics logo
$16.44 +0.38 (+2.37%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$16.43 -0.01 (-0.03%)
As of 05/2/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Denali Therapeutics EPS Results

Actual EPS
-$0.67
Consensus EPS
-$0.75
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Denali Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$12.75 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Denali Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, February 27, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Denali Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Monday, May 5, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Denali Therapeutics Earnings Headlines

The world’s first multi- trillion-dollar robotics industry …
Robots are standing on the edge of history. No one would know this better than Nvidia's Jensen Huang. In Las Vegas, the CEO of the world's most valuable company did more than just talk. He laid out their vision for building the world's first trillion-dollar robot. Kickstarting a multi-trillion-dollar robotics industry.
See More Denali Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Denali Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Denali Therapeutics and other key companies, straight to your email.

About Denali Therapeutics

Denali Therapeutics (NASDAQ:DNLI), a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

View Denali Therapeutics Profile

More Earnings Resources from MarketBeat